Skip to content
    MCK
    Earnings call· Jun 2026(Q1 FY27)

    MCKESSON Q1 FY27 earnings call MCK

    Aug 5, 2026 Source

    Executive summary

    McKesson Q1 FY27 — Strong Performance Drives Raised Full-Year EPS Guidance

    McKesson delivered a strong first quarter, with broad-based momentum across its segments, particularly in North American Pharmaceutical and Oncology and Multispecialty, leading to a raise in full-year adjusted EPS guidance. The company continues to execute on strategic priorities, including the separation of Medical-Surgical Solutions and investments in AI and infrastructure, while navigating dynamic policy environments like 340B and IRA Part D.

    Highlights

    5

    • Revenues increased 8% to $105.4 billion, exceeding expectations.

    • Adjusted earnings per diluted share increased 20% to $9.93, exceeding expectations.

    • Full-year adjusted EPS guidance raised to $44.20-$45.00, reflecting strong momentum.

    • North American Pharmaceutical segment operating profit increased 19%, driven by specialty distribution and new product launches.

    • Oncology and Multispecialty segment revenue grew 33% (24% ex-Core Ventures) and operating profit grew 41% (15% ex-Core Ventures).

    Concerns

    3

    • Operating profit in Medical-Surgical Solutions decreased 20% to $195 million, driven by product mix and one-time administrative expenses.

    • Negative free cash flow of $372 million in Q1 FY27, though an improvement from prior year.

    • Lower branded pharmaceutical pricing following WAC decreases in January 2026 partially offset revenue growth in North American Pharmaceutical.

    Guidance & targets

    18
    CategoryTargetConfidence
    Adjusted earnings per diluted share
    $44.20 to $45.00
    high materiality
    High
    Revenue growth
    5% to 9%
    high materiality
    High
    Operating profit growth
    9% to 13%
    high materiality
    High
    North American Pharmaceutical revenue growth
    4% to 8%
    medium materiality
    High
    North American Pharmaceutical operating profit growth
    high end of 5.5% to 9.5%
    medium materiality
    High
    Oncology and Multispecialty revenue growth
    14.5% to 18.5%
    medium materiality
    High
    Oncology and Multispecialty operating profit growth
    13.5% to 17.5%
    medium materiality
    High
    Prescription Technology Solutions revenue increase
    2.5% to 6.5%
    medium materiality
    High
    Prescription Technology Solutions operating profit increase
    11% to 15%
    medium materiality
    High
    Medical-Surgical Solutions revenue growth
    1% to 6%
    medium materiality
    High
    Medical-Surgical Solutions operating profit growth
    flat to 4%
    medium materiality
    High
    Corporate expenses
    $580 million to $640 million
    low materiality
    High
    Interest expense
    $380 million to $420 million
    low materiality
    High
    Income attributable to noncontrolling interest
    $295 million to $325 million
    low materiality
    High
    Effective tax rate
    18% to 19%
    low materiality
    High
    Free cash flow
    $4.5 billion to $4.9 billion
    high materiality
    High
    Share repurchases
    approximately $5 billion
    high materiality
    High
    Weighted average diluted shares outstanding
    115.5 million to 117.5 million
    low materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    North American Pharmaceuticals
    Driven by broad-based growth from higher prescription volumes, including an increase in specialty products. Partially offset by lower branded pharmaceutical pricing following WAC decreases in January 2026 and branded to generic conversions, which did not meaningfully impact operating profit. Fundamentals remain strong, supported by stable utilization trends, specialty growth, and the strength of the generic sourcing program.
    		$86.8 billion5%—$894 million
    Oncology and Multispecialty
    Revenues driven by growth across the platform, including organic and new business growth in provider solutions, and contributions from the Core Ventures acquisition (completed June 2, 2025). Excluding Core Ventures, revenues grew approximately 24% and operating profit grew approximately 15%. Growth supported by solid utilization trends in the community setting and stable same-store patient visit growth.
    U.S. Oncology Network providers: 3,400U.S. Oncology Network patients treated annually: 2 millionPRISM Vision providers: 200PRISM Vision locations: 97
    		$14.2 billion33%—$405 million
    Prescription Technology Solutions
    Revenues driven by higher prescription volumes in third-party logistics and access solutions. Operating profit driven by higher demand for access solutions, including prior authorization services. Strong demand across technology solutions with growth driven by both GLP-1 medications and other therapeutic categories.
    Prior authorization requests determined within 30 minutes: 95%
    		$1.6 billion9%—$303 million
    Medical-Surgical Solutions
    Improvement in revenue growth trends compared to prior quarters, driven by growth across alternate sites of care, led by higher volumes of specialty pharmaceuticals. Operating profit decreased due to product mix and one-time administrative expense, partially offset by contributions from the extended care channel. Minority ownership interest from Apollo Funds (approx. 13%) completed June 1.
    		$2.8 billion4%—$195 million

    Operational metrics

    21
    Adjusted earnings per diluted share
    $9.9320%
    Q1 FY27

    Reflecting strong operational performance and the benefit of a lower share count.

    Gross profit
    $3.7 billion13%
    Q1 FY27

    Driven by growth in North American Pharmaceutical and Oncology and Multispecialty, reflecting higher prescription volumes and strength in specialty.

    Operating expenses
    $2.1 billion10%
    Q1 FY27

    Reflecting investments to support growth across the business.

    Operating expenses as percentage of gross profit
    improved by approximately 150 basis pointsyear-over-year
    Q1 FY27

    Continuing positive leverage trends through strong gross profit growth and effective expense management.

    Operating profit
    $1.7 billion16%
    Q1 FY27

    Driven by growth in North American Pharmaceutical, Oncology and Multispecialty, and Prescription Technology Solutions.

    Interest expense
    $75 million
    Q1 FY27

    Reflecting recent financing activities supporting the Medical-Surgical Solutions separation.

    Effective tax rate
    21.5%compared to 21.4% in the prior year
    Q1 FY27

    Can vary quarter-to-quarter, driven by timing and amount of discrete tax items.

    Diluted weighted average shares
    119.2 million5%
    Q1 FY27

    Decrease due to share repurchase activity.

    Share repurchases
    $2.5 billion
    Q1 FY27
    Cash and cash equivalents
    $5.2 billion
    Q1 FY27 end
    Total liquidity
    $10 billion
    Q1 FY27 end

    Well above the minimum threshold.

    Quarterly dividend increase
    15%
    Q1 FY27

    Board of Directors approved the increase in July. Committed to dividend growth commensurate with long-term earnings growth target.

    Oncology and Multispecialty revenue growth (ex-Core Ventures)
    approximately 24%
    Q1 FY27

    Excluding contributions from the Core Ventures acquisition.

    Oncology and Multispecialty operating profit growth (ex-Core Ventures)
    approximately 15%
    Q1 FY27

    Excluding contributions from the Core Ventures acquisition.

    Norway divestiture operating profit impact
    $74 million
    FY26

    Completed exit from Norway in January 2026. Q2 FY27 will lap $25 million from Q2 FY26.

    U.S. Oncology Network equity investment gain
    $51 million
    Q2 FY26

    Q2 FY27 will be lapping this gain from the prior year.

    Medical-Surgical Solutions senior secured Term Loan B
    $2.25 billion
    Q1 FY27

    Completed in support of the Medical-Surgical Solutions separation.

    Medical-Surgical Solutions secured Term Loan A
    $1 billion
    Q1 FY27

    Completed in support of the Medical-Surgical Solutions separation.

    Medical-Surgical Solutions revolving credit facility
    $1 billion
    Q1 FY27

    Completed in support of the Medical-Surgical Solutions separation.

    Medical-Surgical Solutions noncash GAAP-only accounting adjustment
    $293 million
    Q1 FY27

    Related to the remeasurement of the redeemable noncontrolling interest following the Apollo Funds transaction.

    Corporate expenses
    $144 million4%
    Q1 FY27

    Primarily reflecting technology infrastructure investments.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trendsstable
    Pharmacy scripts specialty$15 billionUSD
    Segment revenue operating income—
    Adjusted EPS EBITDA leverage guidance$44.20 to $45.00USD

    Deals & partnerships

    2
    Apollo FundsStrategic minority investment in Medical-Surgical Solutions

    Apollo Funds now holds approximately 13% minority ownership interest in MedSurg. Completed on June 1, 2025.

    PfizerStrategic oncology research collaboration to accelerate clinical trials

    Through Sarah Cannon Research Institute (SCRI), leveraging a next-generation clinical trial delivery model to streamline operations, enhance site efficiency, and reduce administrative burden.

    Risks & headwinds

    5
    Lower branded pharmaceutical pricing (WAC decreases)January 2026 (ongoing)

    Impacted revenue in North American Pharmaceutical, but not meaningfully operating profit.

    Mitigation: Fee-for-service contracts ensure minimal impact on operating profit; company manages through dynamics.

    Product mix and one-time administrative expense in Medical-Surgical SolutionsQ1 FY27

    Operating profit decreased 20% to $195 million.

    Mitigation: Focused on disciplined execution and operating efficiencies.

    Dynamic policy environment (e.g., 340B changes, IRA Part D)Ongoing, 340B under review, IRA Part D effective Jan 2028.

    Premature to speculate on financial impact for 340B. IRA Part D not until Jan 2028 with many unknowns.

    Mitigation: McKesson is highly engaged, leveraging scale, technology, and compliance expertise to help customers navigate changes. Advocates for models like GLOBE that protect community providers.

    Quarterly variability in Prescription Technology Solutions performanceQuarter-to-quarter

    Not quantified, but noted as 'not always linear'.

    Mitigation: Driven by utilization trends, product launch timing, program support requirements. Visibility into opportunities and strength of existing programs support expectations.

    Accelerated investments in North American PharmaceuticalSecond half of fiscal '27

    Not quantified, but noted as 'accelerated investments'.

    Mitigation: Focused on growth and AI, with return on investment expected to be accretive to enterprise, likely beginning of FY28.

    What to watch in Q2 FY27

    5

    North American Pharmaceutical Operating Profit Growth

    H2 FY27
    Current+19% in Q1 FY27
    TargetHigh end of 5.5-9.5% for FY27

    Why it matters

    Management noted Q1 benefited from early generic pops and accelerated investments in H2 FY27 could impact later quarters, making the sustained high-end performance important.

    I would say, Michael, that we probably had some favorability in the generics portion of the business that came earlier in the year than we would have expected it to. That obviously will come at the expense of later quarters, we benefited early.

    Q&A highlights

    5

    What drove the strong organic growth and margin expansion in the North American Pharmaceutical segment, given the strong operating earnings growth relative to revenue?

    The strong Q1 performance was driven by increased prescription transaction volume, including higher specialty product volume, and the timing of new product launches (both new branded and branded generics). Operating profit grew faster than revenue due to a higher margin mix from specialty distribution to health systems. Operating margin changes can be influenced by customer mix, product mix (specialty, generics, biosimilars), and channel.

    “On the AOP, we increased 19% for the first quarter. It's really driven by the distribution of specialty products to the health system and timing of new product launches.”

    asked by George Hill · answered by Kenny Cheung

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Priorities & AI Integration

    McKesson is focused on developing talent and leveraging AI to drive measurable business outcomes. A full-day enterprise AI training was hosted at headquarters, bringing teams together for educational sessions and hands-on learning. This investment strengthens operations, innovation, and long-term value creation, with examples demonstrating the potential to scale AI capabilities more broadly across segments.

    02

    Oncology and Multi-Specialty Platform Growth

    The company is capitalizing on specialty therapy growth, serving over 14,000 providers across community-based specialties. The U.S. Oncology Network grew to approximately 3,400 providers, treating over 2 million patients annually, while PRISM Vision expanded to over 200 providers in 97 locations. A strategic oncology research collaboration with Pfizer was announced to accelerate clinical trials, leveraging a next-generation delivery model.

    03

    Biopharma Services and GLP-1 Support

    McKesson enables connectivity across providers, biopharma, pharmacies, and payers, advancing access and affordability programs. The company began supporting the CMS Medicare GLP-1 Bridge program in July, facilitating eligibility determination, electronic prior authorization, and pharmacy claims. New program wins demonstrate broad demand for their technology-driven solutions across various therapeutic categories, improving patient access to therapy.

    04

    North American Distribution & Infrastructure

    The core distribution business delivered strong growth, supported by stable fundamentals and diversified channel reach. McKesson broke ground on a new regional distribution center in Moore, Oklahoma, representing an important investment to strengthen supply chain resiliency. This facility will increase throughput by 75% compared to the prior facility, supported by advanced automation, digitally enabled logistics, and expanded cold chain capabilities.

    05

    Medical-Surgical Solutions Separation (Wellverse)

    The planned separation of Medical-Surgical Solutions is progressing, with the business now branded as Wellverse, anticipating formal operation starting January 2027. A strategic minority investment from Apollo Funds was completed, and a $2.25 billion senior secured Term Loan B was established, further building a stand-alone capital structure. These actions support financial flexibility and reinforce focus on maximizing long-term shareholder value.

    06

    Policy Environment Engagement

    McKesson remains highly engaged in the dynamic policy environment, focusing on the important role of community-based care, access, cost, and transparency. The company became a signatory to technology pledges under the CMS Healthcare Technology Ecosystem initiative. As a diversified health care services company, it aims to strengthen the pharmaceutical supply chain, improve access and affordability, and enable innovation for better patient outcomes.

    AI-generated summary of the company’s earnings call. Not investment advice.